Category: Cancer

The first generic version of Revlimid, known as lenalidomide, was launched in the United States in March 2022 by Teva Pharmaceuticals, marking a significant development for patients needing this expensive medication. This introduction followed a complex series of legal agreements that initially limited the generic's volume and availability.

Research has consistently shown that certain systemic medications, particularly long-term immunosuppressants and photosensitizing drugs, can significantly increase an individual's risk of developing malignant melanoma. For patients concerned about **what drugs cause melanoma**, it's crucial to understand these pharmaceutical connections and their underlying mechanisms to engage in proactive skin health management.